Target intelligence / Profile preview

Gut mucosal surface and intestinal microbiota

Molecular classification
Other
01

Overview

The gut mucosal surface and intestinal microbiota constitute a dynamic interface between the host and the external environment, playing a critical role in maintaining systemic homeostasis. The mucosal layer acts as a selective barrier that facilitates nutrient absorption while preventing the translocation of pathogens and toxins into the bloodstream (NIH, 2023). Coexisting with this surface is the intestinal microbiota, a vast community of microorganisms that contributes to the fermentation of non-digestible carbohydrates, the synthesis of essential vitamins like B12 and K, and the maturation of the host immune system (Nature Reviews Microbiology, 2022). Dysregulation of this ecosystem, often termed dysbiosis, is a hallmark of various pathologies, including inflammatory bowel disease (IBD), metabolic syndrome, and certain cancers (PubMed, 2021). Therapeutic approaches targeting this system range from broad-spectrum antibiotics and fecal microbiota transplantation to more targeted interventions like probiotics and prebiotics designed to restore ecological balance (StatPearls, 2023). Because this represents a complex biological compartment rather than a single molecular entity, it is generally classified as a therapeutic site or environment rather than a discrete drug target.

Other names
Gut microbiomeIntestinal floraGastrointestinal mucosaGut-microbiota axisIntestinal microenvironment
02

Mechanism of action

Modulation of microbial community composition, enhancement of mucosal barrier integrity, and regulation of microbial metabolite production.

03

Biological functions

Immune responseMetabolismBarrier functionPathogen defenseVitamin synthesis
04

Disease associations

Inflammatory bowel diseaseIrritable bowel syndromeClostridioides difficile infectionObesityColorectal cancerMetabolic syndrome
05

Safety considerations

Risk of dysbiosisBacterial translocationAntibiotic resistanceTransfer of pathogens via fecal transplantSystemic inflammation
06

Interacting drugs

Vancomycin

6 more in the full profile.

07

Biomarkers

Fecal calprotectinMicrobial alpha diversityShort-chain fatty acid levels16S rRNA sequencing profiles

Beyond the preview

Go deeper on Gut mucosal surface and intestinal microbiota.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gut mucosal surface and intestinal microbiota.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call